Tarsier Pharma IPO: NYSE Listings Expand with New Opportunities
Decision brief
Answer first · skim in under a minute
Tarsier Pharma is set to launch its IPO on the NYSE, targeting a share price between $8 and $10. This move marks a significant expansion in the pharmaceutical sector.
Tarsier Pharma Ltd. amended its U.S. IPO registration on 8 June 2026, targeting a New York Stock Exchange listing under the symbol TARX at an anticipated $8.00 to $10.00 per ordinary share. SEC filings—not secondary IPO chatter—set the price range, share count assumptions, and use of proceeds.
Contents11 sections
Key Takeaways
- F-1/A filed with the SEC on 8 June 2026 (Accession 0001213900-26-066188); prior amendment dated 18 May 2026.
- Anticipated IPO price range $8.00–$10.00; prospectus share count assumes $9.00 midpoint.
- Proposed NYSE ticker TARX; listing is a closing condition and not guaranteed.
- Free-writing prospectus cites ~5,000,000 ordinary shares offered (15% overallotment) and ~$45M gross at $9 midpoint for TRS01 Phase 3 and related R&D.
What does Tarsier’s SEC IPO filing say?
Tarsier’s Form F-1/A prospectus (subject to completion, dated 8 June 2026) states the company anticipates an initial public offering price between $8.00 and $10.00 per ordinary share.
The company has applied to list on the NYSE under “TARX”. The offering is contingent on NYSE listing approval; the prospectus warns no assurance that approval or a trading market will follow.
How large is the proposed raise?
A free writing prospectus summarises 5,000,000 ordinary shares with a 15% overallotment and expected gross offering size of $45,000,000 at a $9 assumed midpoint.
- Price range: $8–$10
- Proposed symbol: TARX
- Issuer domicile: Israel (incorporated 2016)
Where will proceeds go?
The FWP lists intended uses: advance TRS01 through Phase 3 initiation and completion; prepare toward a potential NDA for TRS01; support IND-enabling work for TRS02; repay certain indebtedness/deferred CEO compensation; and fund working capital and IP protection.
What should EU investors note?
Tarsier is an Israeli issuer seeking a U.S. listing. EU readers should treat the F-1/A as a registration statement still subject to completion—not a priced, allocated IPO—until a final prospectus and pricing press release appear on EDGAR or a wire.
What remains unproven?
No assurance of NYSE approval, final price, or deal size. Clinical success of TRS01 Phase 3 and any NDA outcome are not established by the registration statement. Avoid citing unofficial $8–$10 “targets” without the SEC document.
How to verify updates?
Follow CIK 0002102720 on sec.gov for later F-1 amendments, pricing 424B filings, and Form 8-A listing registration. Prefer EDGAR over unsourced IPO calendars.
What clinical programme is TRS01?
Tarsier’s offering materials state IPO proceeds will advance TRS01 through Phase 3 initiation and completion and support preparations toward a potential NDA. A separate TRS02 programme is flagged for IND-enabling work funded in part by the raise.
Because the F-1/A remains subject to completion, treat Phase 3 design details, endpoints, and timelines as evolving until a final prospectus or later clinical disclosure updates EDGAR. Listing under TARX is contingent on NYSE approval, which the registration statement does not guarantee.
Related NovaPharma coverage
Frequently Asked Questions
What price range did Tarsier file for its IPO?
The F-1/A dated 8 June 2026 anticipates an offering price between $8.00 and $10.00 per ordinary share.
What ticker is Tarsier seeking?
The company applied to list ordinary shares on the NYSE under the symbol TARX, contingent on exchange approval.
What is the main use of IPO proceeds?
Filings state proceeds are intended primarily to advance TRS01 Phase 3 development and related NDA preparation, plus TRS02 IND work and corporate uses.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
